Dysregulated Protein Arginine Deiminase (PAD) activity, particularly PAD4, has been suggested to play a role in the onset and progression of numerous human diseases, including Rheumatoid Arthritis (RA). Given the potential role of PAD4 in RA, we set out to develop inhibitors/ inactivators that could be used to modulate PAD activity and disease progression. This effort led to the discovery of two mechanism-based inactivators, denoted F-and Cl-amidine, that inactivate PAD4 via the covalent modification of an active site cysteine that is critical for catalysis. To gain further insights into the mechanism of inactivation by these compounds, the effect of pH on the rates of inactivation were determined. These results, combined with the results of solvent isotope effect and proton inventory studies, strongly suggest that the inactivation of PAD4 by F-and Clamidine proceeds via a multi-step mechanism that involves the protonation and stabilization of the tetrahedral intermediate formed upon nucleophilic attack by the active site cysteine, i.e. Cys645. Stabilization of this intermediate would help to drive the halide-displacement reaction, which results in the formation of a three-membered sulfonium ring that ultimately collapses to form the inactivated enzyme. This finding -that protonation of the tetrahedral intermediate is important for enzyme inactivation -may also suggest that during catalysis, protonation of the analogous intermediate is required for efficient substrate turnover.
KeywordsDeiminase; Citrulline; Cl-amidine; rheumatoid arthritis; inactivator In nature, a myriad of posttranslational modifications are found in proteins. These modifications, and the requisite modifying enzymes, can have far-reaching effects on living systems. Within the family of protein modifying enzymes are the Protein Arginine Deiminases (PADs). These enzymes catalyze the hydrolysis of arginine residues to form citrulline.[1-3] Much effort from our lab has been focused on gaining insight into the mechanism of the PADs, and, in particular, PAD4. [3-5] Our interest in PAD4, and the